Contributors to nonadherence and nonpersistence with endocrine therapy in breast cancer survivors recruited from an online research registry

Breast Cancer Research and Treatment

Volumn 145, Issue 2, 2014, Pages 525-534

  Stanton, Annette L ^a   Petrie, Keith J ^b   Partridge, Ann H ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Adherence; Aromatase inhibitor; Breast cancer; Compliance; Tamoxifen

Indexed keywords

ANASTROZOLE; EXEMESTANE; LETROZOLE; TAMOXIFEN; TAMOXIFEN CITRATE; TRASTUZUMAB; AROMATASE INHIBITOR;

ADULT; AGED; ANXIETY; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVOR; DEPRESSION; DOCTOR PATIENT RELATION; EDUCATIONAL STATUS; ETHNICITY; FEMALE; HEALTH BEHAVIOR; HEALTH CARE COST; HEALTH CARE QUALITY; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; MEDICATION COMPLIANCE; ONLINE SYSTEM; PATIENT ATTITUDE; PRIORITY JOURNAL; QUESTIONNAIRE; SELF REPORT; SOCIAL STATUS; VERY ELDERLY; BREAST NEOPLASMS; MIDDLE AGED; PATIENT COMPLIANCE; PSYCHOLOGY; REGISTER; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; SURVIVOR;

ADULT; AGED; AGED, 80 AND OVER; AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HUMANS; LOGISTIC MODELS; MIDDLE AGED; PATIENT COMPLIANCE; PHYSICIAN-PATIENT RELATIONS; QUESTIONNAIRES; REGISTRIES; SURVIVORS;

EID: 84901670665     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-2961-3     Document Type: Article

References (52)

1. Burstein HJ, Prestrud AA, Seidenfeld J et al (2010) American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28:3784-3796
2. Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: A systematic review. Breast Cancer Res Treat 134:459-478
3. McCowan C, Shearer J, Donnan PT, Dewar JA, Crilly M, Thompson AM, Fahey TP (2008) Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 99:1763-1768
4. Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C (2013) Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer 108:1515-1524
5. Hershman DL, Shao T, Kushi LH et al (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126:529-537
6. Weaver KE, Camacho F, Hwang W, Anderson R, Kimmick G (2013) Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival in low income women. Am J Clin Oncol 36:181-187
7. Haynes RB, Sackett DL (1979) Compliance in health care. Johns Hopkins University Press, Baltimore, MD
8. Liu Y, Malin JL, Diamant AL, Thind A, Maly RC (2013) Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication. Breast Cancer Res Treat 137:829-836
9. DiMatteo MR, Lepper HS, Croghan TW (2000) Depression is a risk factor for noncompliance with medical treatment: A meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 160:2101-2107 (Pubitemid 30482715)
10. Grenard JL, Munjas BA, Adams JL, Suttorp M, Maglione M, McGlynn EA, Gellad WF (2011) Depression and medication adherence in the treatment of chronic diseases in the United States: A meta-analysis. J Gen Intern Med 26:1175-1182
11. Gonzalez JS, Batchelder AW, Psaros C, Safren SA (2011) Depression and HIV/AIDS treatment adherence: A review and meta-analysis. J Acquir Immun Defic Syndr 58:181-187
12. Hay JL, McCaul KD, Magnan RE (2006) Does worry about breast cancer predict screening behaviors? A meta-analysis of the prospective evidence. Prev Med 42:401-408 (Pubitemid 44183746)
13. Demissie S, Silliman RA, Lash TL (2001) Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol 19:322-328 (Pubitemid 32112842)
14. Grunfeld EA, Hunter MS, Sikka P, Mittal S (2005) Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Counsel 59:97-102 (Pubitemid 41399883)
15. Lash TL, Fox MP, Westrup LJ, Fink AK, Silliman RA (2006) Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 99:215-220 (Pubitemid 44268270)
16. Owusu C, Buist DS, Field TS et al (2008) Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol 26:549-555 (Pubitemid 351264347)
17. Fink AK, Gurwitz J, Rakowski W, Guadagnoli E, Silliman RA (2004) Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol 22:3309-3315 (Pubitemid 41103687)
18. Ziller V, Kalder M, Albert U-S, Holzhauer W, Ziller M, Wagner U, Hadji P (2009) Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Annals Oncol 20:431-436
19. Horne R, Weinman J (1999) Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 47:555-567 (Pubitemid 30029305)
20. Gierisch JM, Earp JA, Brewer NT, Rimer BK (2010) Longitudinal predictors of nonadherence to maintenance of mammography. Cancer Epidemiol Biomarkers Prev 19:1103-1111
21. Zigmond AS, Snaith RP (1983) The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 67:361-370 (Pubitemid 13098606)
22. Vodermaier A, Linden W, Siu C (2009) Screening for emotional distress in cancer patients: A systematic review of assessment instruments. J Natl Cancer Inst 101:1464-1488
23. Tracey TJ, Kokotovic AM (1989) Factor structure of the working alliance inventory. Psychol Assess 1:207-210
24. Busseri MA, Tyler JD (2003) Interchangeability of the working alliance inventory and working alliance inventory, short form. Psychol Assess 15:193-197 (Pubitemid 36750527)
25. Horvath AO, Greenberg LS (1989) Development and validation of the working alliance inventory. J Counseling Psychol 36:223-233
26. Stanton AL, Bernaards CA, Ganz PA (2005) The BCPT Symptom Scales: A measure of physical symptoms for women diagnosed with or at risk for breast cancer. J Natl Cancer Inst 97:448-456 (Pubitemid 40528608)
27. Zivian MT, Salgado B (2008) Side effects revisited: women's experiences with aromatase inhibitors. Breast Cancer Action. http://archive.bcaction.org/ uploads/PDF/AIReport.pdf
28. Crites SL, Fabrigar LR, Petty RE (1994) Measuring the affective and cognitive properties of attitudes: conceptual and methodological issues. Pers Soc Psychol Bull 20:619-634
29. Morisky DE, Green LW, Levine DM (1986) Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 24:67-74 (Pubitemid 16125389)
30. Lavsa SM, Holzworth A, Ansani NT (2011) Selection of a validated scale for measuring medication adherence. J Am Pharm Assoc 51:90-94
31. Horne R, Weinman J (2002) Self-regulation and self-management in asthma: exploring the role of illness perceptions and treatment beliefs in explaining non-adherence to preventer medication. Psychol Health 17:17-32
32. ATAC Trialists' Group (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-62 (Pubitemid 40082147)
33. Lin JH, Zhang SM, Manson JE (2011) Predicting adherence to tamoxifen for breast cancer adjuvant therapy and prevention. Cancer Prev Res 4:1360-1365
34. Sedjo RL, Devine S (2011) Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Breast Cancer Res Treat 125:191-200
35. Wigertz A, Ahlgren J, Holmqvist M, Fornander T, Adolfsson J, Lindman H, Bergkvist L, Lambe M (2012) Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: A population-based study. Breast Cancer Res Treat 133:367-373
36. Hart SL, Hoyt MA, Diefenbach M, Anderson DR, Kilbourn KM, Craft LL, Steel JL, Cuijpers P, Mohr DC, Berendsen M, Spring B, Stanton AL (2012) Meta-analysis of efficacy of interventions for elevated depressive symptoms in adults diagnosed with cancer. J Natl Cancer Inst 104:990-1004
37. Schneider S, Moyer A, Knapp-Oliver S, Sohl S, Cannella D, Targhetta V (2010) Pre-intervention distress moderates the efficacy of psychosocial treatment for cancer patients: A meta-analysis. J Behav Med 33:1-14
38. Haskard-Zolnierek KB, DiMatteo MR (2009) Physician communication and patient adherence to treatment: A meta-analysis. Med Care 47:826-834
39. McCorkle R, Ercolano E, Lazenby M, Schulman-Green D, Schilling LS, Lorig K, Wagner EH (2011) Self-management: enabling and empowering patients living with cancer as a chronic illness. CA Cancer J Clin 61:50-62
40. Partridge AH, Wang PS, Winer EP, Avorn J (2003) Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 15:602-606 (Pubitemid 46621892)
41. Garber MC, Nau DP, Erickson SR, Aikens JE, Lawrence JB (2004) The concordance of self-report with other measures of medication adherence: A summary of the literature. Med Care 42:649-652
42. Waterhouse DM, Calzone KA, Mele C, Brenner DE (1993) Adherence to oral tamoxifen: A comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol 11:1189-1197 (Pubitemid 23163362)
43. Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, Frick PA (2006) Self-report measures of antiretroviral therapy adherence: A review with recommendations for HIV research and clinical management. AIDS Behav 10:227-245
44. Phillips KA, Milne RL, Buys S, Friedlander ML, Ward JH, McCredie MR, Giles GG, Hopper JL (2005) Agreement between self-reported breast cancer treatment and medical records in a population-based Breast Cancer Family Registry. J Clin Oncol 23:4679-4686 (Pubitemid 46224070)
45. Bjorner JB, Rose M, Gandek B, Stone AA, Junghaenel DU, Ware JE (2014) Method of administration of PROMIS scales did not significantly impact score level, reliability, or validity. J Clin Epidemiol 67:108-113
46. DiMatteo MR (2004) Social support and patient adherence to medical treatment: A meta-analysis. Health Psychol 23:207-218 (Pubitemid 38365280)
47. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X (2008) Interventions for enhancing medication adherence. Cochrane Database Syst Rev, Issue 2. Art. No.: CD000011. doi: 10.1002/14651858.CD000011.pub3 (Pubitemid 351807324)
48. Roter DL, Hall JA, Merisca R, Nordstrom B, Cretin D, Svarstad B (1998) Effectiveness of interventions to improve patient compliance: A meta-analysis. Med Care 36:1138-1161 (Pubitemid 128456406)
49. Hadji P, Blettner M, Harbeck N, Jackisch C, Lück HJ, Windemuth-Kieselbach C, Zaun S, Kreienberg R (2013) The Patient's Anastrozole Compliance to Therapy (PACT) program: A randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer. Ann Oncol 24:1505-1512
50. Ziller V, Kyvernitakis I, Knöll D, Storch A, Hars O, Hadji P (2013) Influence of a patient information program on adherence and persistence with an aromatase inhibitor in breast cancer treatment - the COMPAS study. BMC Cancer 13:407. doi: 10.1186/1471-2407-13-407
51. Duijts SF, van Beurden M, Oldenburg HS et al (2012) Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial. J Clin Oncol 30:4124-4133
52. Ruddy K, Mayer E, Partridge A (2009) Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 59:56-66